Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis

Pancreatic adenocarcinoma is a devastating disease with only 15–20% of patients resectable at diagnosis. Neoadjuvant chemotherapy for this cohort is becoming increasingly popular; however, there are no published randomized trials that support the use of neoadjuvant chemotherapy over upfront surgery...

Descripción completa

Detalles Bibliográficos
Autores principales: Maloney, Sarah, Itchins, Malinda, Arena, Jennifer, Sahni, Sumit, Howell, Viive M., Hayes, Sarah A., Gill, Anthony J., Clarke, Stephen J., Samra, Jaswinder, Mittal, Anubhav, Pavlakis, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235361/
https://www.ncbi.nlm.nih.gov/pubmed/34207372
http://dx.doi.org/10.3390/jcm10122700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235361/
https://www.ncbi.nlm.nih.gov/pubmed/34207372
http://dx.doi.org/10.3390/jcm10122700

Ejemplares similares